Overview

Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia

Status:
Withdrawn
Trial end date:
1999-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Biological therapies use different ways to stimulate the immune system and stop cancer cell from growing. Combining more than one chemotherapy drug with biological therapy may kill more cancer cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, isotretinoin, and interferon alfa in treating patients who have acute myelogenous leukemia.
Phase:
Phase 2
Details
Lead Sponsor:
Rush University Medical Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
5-bromouridine
Amifostine
Bromodeoxyuridine
Cytarabine
Idarubicin
Idoxuridine
Interferon-alpha
Interferons
Isotretinoin
Mitoxantrone